HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Trial details
- Registry ID
- NCT06634420
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)NCT06634420 | Intellia Therapeutics | Phase 3 | Active not recruiting | 2026-02-10Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |